OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
PHIO
Phio Pharmaceuticals Corp.
Common Stock
2.27
-0.20
-8.10%
Delayed (15 Min) Trade Data: 12:00am 06/13/2025
Phio Pharmaceuticals Corp.
11 Apex Drive
Suite 300A
Marlborough, MA 01752
Business Description
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAI technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001533040
Fiscal Year End
12/31
Company Officers & Contacts
Geert Cauwenbergh
President, CEO
Tamara McGrillen
IR
Board of Directors
Robert J. Bitterman
Chairman
Keith L. Brownlie
Geert Cauwenbergh
President, CEO
H. Paul Dorman
Curtis Lockshin
Other Company Insiders
Not available
Service Providers
Accounting/Auditing Firm
BDO USA, LLP945 E Park Drive
Suite 103
Harrisburg, PA 17111
Securities Counsel
Ropes & Gray3 Embarcadero Center
San Francisco, CA 94111
Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
DE, US, 2011
Employees
10 as of 04/30/2013
Shell
No
Products and Services
Not available
Company Facilities
Not available
Company Notes
Formerly=RXI Pharmaceuticals Corporation until 11-2018
Loading...
Symbol
OTCM
Last
51.15
Change
0.15 (0.29%)
Bid
51.15
Ask
51.40
Volume
13900
Time
00:00
